文献速递儿童青少年精神

芬太尼抑制拉诺固醇后生物合成:对胎儿芬太尼综合征(FFS)的潜在意义

Inhibition of post-lanosterol biosynthesis by fentanyl: potential implications for Fetal Fentanyl Syndrome (FFS).
PubMed 文献 · Mol Psychiatry · 2024-06-06

研究提出胎儿芬太尼综合征(FFS)可能由母亲芬太尼使用障碍所致,以新生儿7-脱氢胆固醇(7-DHC)升高为生化特征。作者用Neuro2a细胞、原代小鼠神经元与星形胶质细胞培养及DHCR7+/+与DHCR7+/-基因型人真皮成纤维细胞(HDFs)进行体外实验,发现芬太尼干扰全部四种模型的固醇生物合成,升高7-DHC并降低脱氢胆固醇(DES)。DHCR7+/- HDFs对芬太尼的固醇合成抑制作用显著更敏感。

要点

  • 芬太尼体外暴露干扰全部四种模型的固醇生物合成,升高7-DHC并降低DES。
  • 芬太尼对拉诺固醇后通路的干扰复杂,不限于单纯DHCR7抑制。
  • DHCR7+/- HDFs对芬太尼固醇合成抑制作用的敏感性显著高于DHCR7+/+。

核心结论

  • 母亲在阿片类使用障碍背景下使用芬太尼,可能通过强烈干扰整个拉诺固醇后通路而导致发育中的胎儿发生FFS,其机制比单纯DHCR7抑制更复杂。
  • 母亲和/或发育中孩子的DHCR7+/-杂合性(可能还包括其他固醇生物合成基因),与母亲芬太尼使用障碍合并时,可能是暴露子代发生FFS的重要促发因素。
  • 作者认为,在药物安全性评估中,尤其是妊娠期,应将评估新药和现有药物对固醇生物合成的影响作为必要考虑。

研究设计与样本

  • 研究对Neuro2a细胞、原代小鼠神经元与星形胶质细胞培养以及DHCR7+/+和DHCR7+/-基因型人真皮成纤维细胞(HDFs)进行了一系列体外实验。

主要发现

  • 体外芬太尼暴露干扰全部四种体外模型的固醇生物合成。
  • 芬太尼导致的固醇生物合成干扰复杂,涵盖大多数拉诺固醇后中间产物,在所有研究模型中均表现为7-DHC升高和脱氢胆固醇(DES)降低。
  • 后续实验发现,DHCR7+/- HDFs对芬太尼的固醇生物合成抑制作用的敏感性显著高于野生型DHCR7+/+成纤维细胞。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A recent study discovered a novel, complex developmental disability syndrome, most likely caused by maternal fentanyl use disorder. This Fetal Fentanyl Syndrome (FFS) is biochemically characterized by elevated 7-dehydrocholesterol (7-DHC) levels in neonates, raising the question if fentanyl inhibition of the dehydrocholesterol reductase 7 (DHCR7) enzyme is causal for the emergence of the pathophysiology and phenotypic features of FFS. To test this hypothesis, we undertook a series of experiments on Neuro2a cells, primary mouse neuronal and astrocytic cultures, and human dermal fibroblasts (HDFs) with DHCR7+/+ and DHCR7+/- genotype. Our results revealed that in vitro exposure to fentanyl disrupted sterol biosynthesis across all four in vitro models. The sterol biosynthesis disruption by fentanyl was complex, and encompassed the majority of post-lanosterol intermediates, including elevated 7-DHC and decreased desmosterol (DES) levels across all investigated models. The overall findings suggested that maternal fentanyl use in the context of an opioid use disorder leads to FFS in the developing fetus through a strong disruption of the whole post-lanosterol pathway that is more complex than a simple DHCR7 inhibition. In follow-up experiments we found that heterozygous DHCR7+/- HDFs were significantly more susceptible to the sterol biosynthesis inhibitory effects of fentanyl than wild-type DHCR7+/+ fibroblasts. These data suggest that DHCR7+/- heterozygosity of mother and/or developing child (and potentially other sterol biosynthesis genes), when combined with maternal fentanyl use disorder, might be a significant contributory factor to the emergence of FFS in the exposed offspring. In a broader context, we believe that evaluation of new and existing medications for their effects on sterol biosynthesis should be an essential consideration during drug safety determinations, especially in pregnancy.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Korade Z, Anderson AC, Sharma K, et al. Inhibition of post-lanosterol biosynthesis by fentanyl: potential implications for Fetal Fentanyl Syndrome (FFS). Mol Psychiatry. 2024. PMID: 38844533. doi:10.1038/s41380-024-02622-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。